Stockreport

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

XORTX Therapeutics Inc.  (XRTX) 
PDF CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) --  XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage cli [Read more]